Anthem BioScience Files Draft Papers For Rs 3,395-Crore IPO
The equity shares are proposed to be listed on the National Stock Exchange and the BSE.
Anthem BioScience Ltd. filed its preliminary papers with the Securities and Exchange Board of India on Tuesday to raise Rs 3,395 crore via an initial public offering.
The public offer will include only an offer for sale worth Rs 3,395 crore. The equity shares are proposed to be listed on the National Stock Exchange and the BSE.
Ganesh Sambasivan and K Ravindra Chandrappa are the promoters of the company offloading shares in the OFS. While Viridity Tone LLP and Portsmouth Technologies LLC are the investors that will sell their shares. Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan and K Ramakrishnan will also be selling their shares in the public offering.
JM Financial Ltd., Citigroup Global Markets India Pvt., J.P. Morgan India Pvt. and Nomura Financial Advisory and Securities (India) Pvt. are the book-running lead manager and KFin Technologies Ltd. will be the registrar of the issue.
The Bengaluru-based company will not get any proceeds as the IPO only includes an offer for sale.
Anthem BioScience is a technology focused contract research, development and manufacturing organisation with fully integrated operations spanning across drug discovery, development and manufacturing. The company has developed various platforms such as RNA interference, Antibody-Drug Conjugates, peptides, lipids and oligonucleotides over time.
The pharmaceutical company was founded in 2006 by Ajay Bhardwaj, a former Biocon executive who serves as its CEO and Managing Director. Initially focused on early-stage drug discovery services, the company has since expanded into contract manufacturing. Anthem competes with leading Indian API manufacturers such as Syngene International and Divi's Laboratories.
